임상 한눈에 보기

• 7건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 1, Phase 2 · Phase 1 · Phase 2
• Status: Completed · Unknown status · Terminated…
• 주요 endpoint: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Dose Limiting Toxicities (DLTs) · Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) · Median Progression-free Survival (PFS) as Measured by Response Evaluation in Solid Tumors 1.1 (RECIST 1.1) Using Kaplan-Meier Method · Objective Response Rate as Measured by as Measured by Response Evaluation in Solid Tumors 1.1 (RECIST 1.1) · Progression-free Survival (PFS) at Week 24 as Measured by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)
• 등록 대상자(표본 합산): 약 136명
• 등록된 결과: ORR 5%
• 핵심: This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unres…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.